{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:17:55Z","timestamp":1795090675456,"version":"4.10.2"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Atrial fibrillation (AF) significantly increases stroke risk and hence requires anticoagulation for the prevention of stroke. This review discusses strategies of anticoagulation, including the paradigm shift from traditional vitamin K antagonists (VKAs), such as warfarin, to direct oral anticoagulants (DOACs): dabigatran, rivaroxaban, apixaban, and edoxaban. VKAs are effective but require regular monitoring of international normalized ratio and also pose challenges because of their drug and dietary interactions. In contrast, DOACs provide predictable pharmacokinetics, fewer interactions, and no requirement for routine monitoring, and their use is increasingly favored in clinical practice. The review puts an emphasis on the considerations that are patient-specific when choosing an anticoagulant agent, including age, renal function, and associated diseases; stroke risk or risk factors for bleeding; and it explains how tools such as the use of CHA2DS2-VASc and HAS-BLED scores can be relevant for assessing stroke and bleeding risk, respectively. Also, it is explored that the use of emerging therapies like factor XI inhibitors and combinations such as dual antiplatelet therapy with anticoagulants has the potential to provide maximum stroke prevention but fewer bleeding complications. This review evaluated the effect of reversal agents for anticoagulants that may act as a safety measure during instances of serious bleeding. In summary, AF anticoagulation has to be individually tailored based on patient characteristics and meticulous reading of clinical guidelines. As much as DOACs present a tremendous step forward in stroke prevention related to AF, future studies and emerging treatments show promise to further optimize therapeutic outcomes.<\/jats:p>","DOI":"10.1097\/ms9.0000000000003364","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T06:03:09Z","timestamp":1746856989000},"page":"3691-3699","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Anticoagulation strategies for stroke prevention in atrial fibrillation: a comprehensive review of current literature"],"prefix":"10.1097","volume":"87","author":[{"given":"Zainab Aslam","family":"Castro-Vidal","sequence":"first","affiliation":[{"name":"Department of Surgery, Saba University School of Medicine, The Bottom, Saba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1075-2429","authenticated-orcid":false,"given":"Asad","family":"Gandapur","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine - Pulmonary, Critical Care and Sleep Medicine Division, University of Nebraska Medical Center, Omaha, Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5761-0163","authenticated-orcid":false,"given":"Rohit","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Oncology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, North Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9701-4961","authenticated-orcid":false,"given":"Khaled","family":"Azab","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5069-9895","authenticated-orcid":false,"given":"Khushi","family":"Nayyar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Adesh Institute of Medical Sciences and Research, Bathinda, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0668-4218","authenticated-orcid":false,"given":"Fnu","family":"Rinkoo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8936-8273","authenticated-orcid":false,"given":"Sravani","family":"Kommuru","sequence":"additional","affiliation":[{"name":"Dr Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8801-7120","authenticated-orcid":false,"given":"Youssef","family":"Elsoussi","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Sharjah, Sharjah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagavenakta Lova Surya Vamsi Avinash","family":"Bojanki","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Siddhartha Medical College, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Kumar","family":"Yennam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Emilio Aguinaldo College, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeed Mahmud","family":"Nishat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Shaheed Suhrawardy Medical College, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7281-6453","authenticated-orcid":false,"given":"Jatin","family":"Motwani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Liaquat National Hospital and Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"R1-20251204","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/ijms23010006","article-title":"Atrial fibrillation: pathogenesis, predisposing factors, and genetics","volume":"23","author":"Sagris","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R2-20251204","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ Res"},{"key":"R3-20251204","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the FRAMINGHAM HEART STUDY: A COHORT study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"R5-20251204","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0041-1726332","article-title":"Atrial fibrillation and ischemic stroke: a clinical review","volume":"41","author":"Migdady","year":"2021","journal-title":"Semin Neurol"},{"key":"R6-20251204","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"R7-20251204","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1161\/CIR.0000000000000748","article-title":"Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association","volume":"141","author":"Chung","year":"2020","journal-title":"Circulation"},{"key":"R8-20251204","first-page":"442","article-title":"Diagnosis and treatment of atrial fibrillation","volume":"94","author":"Gutierrez","year":"2016","journal-title":"Am Fam Physician"},{"key":"R9-20251204","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14779072.2023.2160319","article-title":"Atrial fibrillation and stroke","volume":"21","author":"Choi","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R10-20251204","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tcm.2021.12.001","article-title":"Atrial fibrillation and stroke: a review and new insights","volume":"33","author":"Escudero-Mart\u00ednez","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"R11-20251204","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1161\/CIRCULATIONAHA.122.060666","article-title":"Early versus delayed non-vitamin k antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): a registry-based randomized controlled noninferiority study [published correction appears in circulation","volume":"146","author":"Oldgren","year":"2022","journal-title":"Circulation"},{"key":"R12-20251204","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/heartjnl-2019-314898","article-title":"Stroke and thromboembolism prevention in atrial fibrillation","volume":"106","author":"Jame","year":"2020","journal-title":"Heart"},{"key":"R13-20251204","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/eurheartj\/ehy879","article-title":"Risk stratification for stroke in atrial fibrillation: a critique","volume":"40","author":"Killu","year":"2019","journal-title":"Eur Heart J"},{"key":"R14-20251204","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"R15-20251204","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1517\/14656566.9.5.677","article-title":"Warfarin therapy: in need of improvement after all these years","volume":"9","author":"Kimmel","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R16-20251204","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2165\/00003088-199630060-00002","article-title":"Clinically important drug interactions with anticoagulants. An update","volume":"30","author":"Harder","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"R17-20251204","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R18-20251204","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1253\/circj.CJ-11-0191","article-title":"Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation\u2013sub-analysis in Japanese population in RE-LY trial","volume":"75","author":"Hori","year":"2011","journal-title":"Circ J"},{"key":"R19-20251204","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1161\/STROKEAHA.122.041628","article-title":"Clinical outcomes of anticoagulated patients with atrial fibrillation after falls or head injury: insights from RE-LY","volume":"54","author":"Caldeira","year":"2023","journal-title":"Stroke"},{"key":"R20-20251204","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2018.04.063","article-title":"Concomitant oral anticoagulant and nonsteroidal anti-inflammatory drug therapy in patients with atrial fibrillation","volume":"72","author":"Kent","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R21-20251204","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jclinepi.2021.07.001","article-title":"An emulated target trial analysis based on Medicare data suggested non-inferiority of dabigatran versus rivaroxaban","volume":"139","author":"Mei","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"R22-20251204","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2022.03.050","article-title":"Comparison of dabigatran versus warfarin treatment for prevention of new cerebral lesions in valvular atrial fibrillation","volume":"175","author":"Cho","year":"2022","journal-title":"Am J Cardiol"},{"key":"R23-20251204","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"R24-20251204","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijcard.2017.06.110","article-title":"Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: results from ROCKET AF","volume":"257","author":"Barnett","year":"2018","journal-title":"Int J Cardiol"},{"key":"R25-20251204","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2018.01.141","article-title":"The EXPAND study: efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation","volume":"258","author":"Shimokawa","year":"2018","journal-title":"Int J Cardiol"},{"key":"R26-20251204","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2022.03.037","article-title":"RIvaroxaban in mitral stenosis (RISE MS): a pilot randomized clinical trial","volume":"356","author":"Sadeghipour","year":"2022","journal-title":"Int J Cardiol"},{"key":"R27-20251204","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"key":"R28-20251204","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10557-023-07470-z","article-title":"Rivaroxaban in valvular atrial fibrillation - a critical appraisal of the INVICTUS trial","volume":"38","author":"Hammer","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"R29-20251204","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"key":"R30-20251204","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease [published correction appears in","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"R31-20251204","first-page":"e114","article-title":"On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF","volume":"134","author":"Fordyce","year":"2016","journal-title":"Circulation"},{"key":"R32-20251204","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjmed.2019.04.013","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis","volume":"132","author":"Coleman","year":"2019","journal-title":"Am J Med"},{"key":"R33-20251204","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R34-20251204","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/ehjqcco\/qcz047","article-title":"Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes","volume":"6","author":"Hernandez","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R35-20251204","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"R36-20251204","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijcard.2013.10.062","article-title":"Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial","volume":"170","author":"Bahit","year":"2013","journal-title":"Int J Cardiol"},{"key":"R37-20251204","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1136\/heartjnl-2017-312272","article-title":"Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease","volume":"104","author":"Vinereanu","year":"2018","journal-title":"Heart"},{"key":"R38-20251204","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial","volume":"42","author":"Guimar\u00e3es","year":"2019","journal-title":"Clin Cardiol"},{"key":"R39-20251204","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.7326\/M22-0318","article-title":"Apixaban versus rivaroxaban in patients with atrial fibrillation and valvular heart disease: a population-based study","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med"},{"key":"R40-20251204","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1053\/j.gastro.2016.12.018","article-title":"Gastrointestinal safety of direct oral anticoagulants: a large population-based study","volume":"152","author":"Abraham","year":"2017","journal-title":"Gastroenterology"},{"key":"R41-20251204","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","article-title":"A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants","volume":"3","author":"Halvorsen","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R42-20251204","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"key":"R43-20251204","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2019.12.060","article-title":"Clinical and pharmacological effects of apixaban dose adjustment in the ARISTOTLE Trial","volume":"75","author":"Zeitouni","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R44-20251204","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"R45-20251204","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jocn.2020.10.036","article-title":"Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: an in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial","volume":"86","author":"Nelson","year":"2021","journal-title":"J Clin Neurosci"},{"key":"R46-20251204","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.amjmed.2016.02.028","article-title":"Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 Trial","volume":"129","author":"Giugliano","year":"2016","journal-title":"Am J Med"},{"key":"R47-20251204","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1161\/CIRCULATIONAHA.119.041346","article-title":"Comparison of events across bleeding scales in the ENGAGE AF-TIMI 48 Trial","volume":"140","author":"Bergmark","year":"2019","journal-title":"Circulation"},{"key":"R48-20251204","first-page":"176","article-title":"Edoxaban in atrial fibrillation patients with established coronary artery disease: insights from ENGAGE AF-TIMI 48","volume":"8","author":"Zelniker","year":"2019","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R49-20251204","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ehjcvp\/pvab089","article-title":"Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48","volume":"8","author":"Bonaca","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R50-20251204","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","article-title":"Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial","volume":"18","author":"Wilkinson","year":"2020","journal-title":"BMC Med"},{"key":"R51-20251204","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jamacardio.2022.0480","article-title":"Effect of 15-mg edoxaban on clinical outcomes in 3 age strata in older patients with atrial fibrillation: a prespecified subanalysis of the ELDERCARE-AF randomized clinical trial","volume":"7","author":"Kuroda","year":"2022","journal-title":"JAMA Cardiol"},{"key":"R52-20251204","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"R53-20251204","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.3346\/jkms.2022.37.e335","article-title":"Outcomes of on-label reduced-dose edoxaban in patients with atrial fibrillation: the LEDIOS registry","volume":"37","author":"Kim","year":"2022","journal-title":"J Korean Med Sci"},{"key":"R54-20251204","doi-asserted-by":"crossref","first-page":"e031506","DOI":"10.1161\/JAHA.123.031506","article-title":"Efficacy and safety of low-dose edoxaban by body weight in very elderly patients with atrial fibrillation: a subanalysis of the randomized ELDERCARE-AF trial","volume":"13","author":"Akao","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R56-20251204","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/01.CIR.0000145172.55640.93","article-title":"Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin","volume":"110","author":"Gage","year":"2004","journal-title":"Circulation"},{"key":"R57-20251204","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22435","article-title":"The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"38","author":"Zhu","year":"2015","journal-title":"Clin Cardiol"},{"key":"R58-20251204","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R59-20251204","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacep.2019.07.008","article-title":"Contraindication to anticoagulation in nonvalvular atrial fibrillation: are we still to fear the clot and not the bleed?","volume":"5","author":"John","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"R60-20251204","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"R61-20251204","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.022","article-title":"Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: a report from a prospective European Observational Registry","volume":"128","author":"Mei","year":"2024","journal-title":"Eur J Intern Med"},{"key":"R62-20251204","doi-asserted-by":"crossref","first-page":"e2024038","DOI":"10.4084\/MJHID.2024.038","article-title":"Clinical care pathway and management of major bleeding associated with nonvitamin k antagonist oral anticoagulants: a modified Delphi consensus from Saudi Arabia and the UAE","volume":"16","author":"Al Raizah","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R63-20251204","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cnur.2023.05.005","article-title":"Anticoagulation for stroke prevention in atrial fibrillation","volume":"58","author":"Palmer","year":"2023","journal-title":"Nurs Clin North Am"},{"key":"R64-20251204","doi-asserted-by":"crossref","first-page":"102426","DOI":"10.1016\/j.rpth.2024.102426","article-title":"A small-molecule hemostatic agent for the reversal of direct oral anticoagulant-induced bleeding","volume":"8","author":"Desvages","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"R65-20251204","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/jth.14476","article-title":"Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran","volume":"17","author":"Glund","year":"2019","journal-title":"J Thromb Haemost"},{"key":"R66-20251204","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.ajem.2020.05.086","article-title":"A review of guidelines on anticoagulation reversal across different clinical scenarios: is there a general consensus?","volume":"38","author":"Milling","year":"2020","journal-title":"Am J Emerg Med"},{"key":"R67-20251204","doi-asserted-by":"crossref","first-page":"109046","DOI":"10.1016\/j.thromres.2024.109046","article-title":"Design and rationale for REVERXaL: a real-world study of patients with factor Xa inhibitor-associated major bleeds","volume":"240","author":"Alikhan","year":"2024","journal-title":"Thromb Res"},{"key":"R68-20251204","first-page":"S221","article-title":"Reversal of anticoagulants in critical care","volume":"23","author":"Chacko","year":"2019","journal-title":"Indian J Crit Care Med"},{"key":"R69-20251204","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tmrv.2021.06.007","article-title":"Roles of four-factor prothrombin complex concentrate in the management of critical bleeding","volume":"35","author":"Tanaka","year":"2021","journal-title":"Transfus Med Rev"},{"key":"R70-20251204","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s43044-024-00570-7","article-title":"The third-generation anticoagulants: factors XI, XII, and XIII inhibitors","volume":"76","author":"Prajapathi","year":"2024","journal-title":"Egypt Heart J"},{"key":"R72-20251204","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3390\/molecules29081848","article-title":"Advanced nano-drug delivery systems in the treatment of ischemic stroke","volume":"29","author":"Zhang","year":"2024","journal-title":"Molecules"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T08:05:43Z","timestamp":1764835543000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003364","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"2024-08-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}